Taddio, Marco F. http://orcid.org/0000-0003-2477-5575
Doshi, Suraj
Masri, Marwan
Jeanjean, Pauline
Hikmat, Firas
Gerlach, Alana
Nyiranshuti, Lea
Rosser, Ethan W.
Schaue, Dorthe
Besserer-Offroy, Elie
Carlucci, Giuseppe
Radu, Caius G.
Czernin, Johannes
Lückerath, Katharina
Mona, Christine E.
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P400PB_199263)
Prostate Cancer Foundation (19CHAL09, TACT01 (2022))
Jonsson Comprehensive Cancer Center (Leader Vision Award)
Article History
Received: 27 April 2024
Accepted: 17 June 2024
First Online: 15 July 2024
Declarations
:
: Johannes Czernin and Caius G. Radu hold equity and are (co-) founders of Trethera Therapeutics and Sofie Biosciences, which has licensed intellectual property of FAPI compounds from the University of Heidelberg. Johannes Czernin serves also on the Medical Advisory Boards of Point Pharma, Actinium Pharmaceuticals and RayzeBio Inc. Christine Mona and Katharina Lueckerath report consulting activities for Sofie Biosciences/iTheranostics outside the submitted work. No other potential conflict of interest relevant to this article was reported.